| Literature DB >> 33024386 |
Chaitra C Rao1, Gunavanthi Jayakumar Himaaldev2.
Abstract
INTRODUCTION: Aluminum phosphide poisoning (ALP) has a high-mortality rate despite intensive care management, primarily because it causes severe myocardial depression. This case report highlights the subset of ALP patients presenting as ST elevation myocardial infarction (STEMI) with profound myocardial dysfunction and multiorgan failure and successfully treated with extracorporeal membrane oxygenation (ECMO), trimetazidine, and magnesium. CASE DESCRIPTION: A 25-year-old man without any comorbidities was brought to emergency department with dyspnea and hypotension. His electrocardiograph (ECG) revealed STEMI with elevated troponin levels, arterial blood gas (ABG) showed severe metabolic acidosis, and echocardiography (echo) revealed ejection fraction 15%. He was initiated on venoarterial (VA) ECMO in view of refractory hypotension. History of consumption of three tabs of celphos was revealed later by the family members. He progressed to cardiogenic shock, arrhythmias, respiratory failure, acute kidney injury with severe lactic acidosis, liver injury, pancreatitis, and disseminated intravascular coagulation (DIC). He was successfully supported by ECMO, hemodialysis, magnesium, trimetazidine, N-acetyl cysteine, inotropes, and blood products. He was weaned off ECMO on day 6 and was discharged home on day 12. Despite his severe and confounding clinical presentation, he had complete normalization of end-organ dysfunction with no neurological sequela. This case demonstrates the high index of suspicion required for ALP, given the potential for rapid progression and severe multiorgan toxicity. This report also highlights the importance of early referral to a tertiary care center with ECMO capability and also the role of magnesium and trimetazidine to suppress arrhythmias.Entities:
Keywords: Aluminum phosphide; Extracorporeal membrane oxygenation; Magnesium; ST elevation myocardial infarction; Trimetazidine
Year: 2020 PMID: 33024386 PMCID: PMC7519610 DOI: 10.5005/jp-journals-10071-23533
Source DB: PubMed Journal: Indian J Crit Care Med ISSN: 0972-5229
Fig. 1ECG changes showing broad QRS complexes
Key laboratory variables with time course of illness
| Hemoglobin (g/dL) | 15.9 | 8.8 | 8.3 | 9.1 | 9.8 | 9.0 | 9.2 | 10 |
| Total WBC count (109/L) | 11.7 | 10.5 | 4.7 | 4.4 | 6.6 | 12.2 | 14 | 13.6 |
| Platelets (109/L) | 324 | 72 | 89 | 83 | 65 | 80 | 85 | 125 |
| Renal function tests | ||||||||
| Sodium (mEq/L) | 137 | 144 | 144 | 143 | 141 | 138 | 140 | 138 |
| Potassium (mEq/L) | 4 | 4.4 | 4.1 | 4.6 | 4.1 | 4.7 | 4.3 | 3.5 |
| Urea (mg/dL) | 24 | 30 | 127 | 144 | 85 | 183 | 144 | 62 |
| Creatinine (mg/dL) | 1.1 | 1.3 | 5.1 | 5.3 | 3.3 | 6 | 4.8 | 2.1 |
| Ischemic hepatitis | ||||||||
| Total bilirubin (mg/dL) | 0.7 | 1.6 | 2.0 | 2.2 | 2.1 | 1.9 | ||
| Alanine transaminase (U/L) | 31 | 1,152 | 7,515 | 5,310 | 1,838 | 441 | 841 | 76 |
| Aspartate transaminase (U/L) | 33 | 1,051 | 3,385 | 2,590 | 1,884 | 1,377 | 166 | 366 |
| Prothrombin time (seconds) | 14.7 | 24.3 | 22.3 | 19.3 | 15.4 | 13.4 | 15.4 | 20.5 |
| International normalized ratio | 1.12 | 1.91 | 1.74 | 1.5 | 1.18 | 1.02 | 1.18 | 1.59 |
| Activated prothrombin time (seconds) | 23.9 | 40.9 | 37.7 | 47.8 | 36 | 27.7 | 27 | 27 |
| Fibrinogen (mg/dL) | 270 | 98 | 110 | 170 | 293 | |||
| Acute pancreatitis | ||||||||
| Amylase (IU/L) | 1,120 | 987 | ||||||
| Lipase (IU/L) | 174.3 | 289.6 | ||||||
Key clinical parameters with time course of illness
| Ejection fraction | 25% | 30% | 35% | 40% | 50% | |||
| Lactate levels (mmol/L) | 8.8 | 4.6 | 2.5 | 2.8 | 1.7 | 1.4 | 1.6 | 1.2 |